Keyphrases
Glioblastoma
100%
Photothermal Therapy
49%
Tumor
48%
Radiation Therapy
30%
Progression-free Survival
27%
Overall Survival
27%
Newly Diagnosed Glioblastoma
26%
Temozolomide
24%
Meningioma
22%
Stereotactic Radiosurgery
21%
CDC20
18%
Laser Ablation
17%
Gross Total Resection
16%
Brain Metastases
16%
Recurrent Glioblastoma
15%
Brain Tumor
15%
Disulfiram
14%
High-grade Glioma
14%
Intraoperative Magnetic Resonance Imaging (iMRI)
13%
Clinical Outcomes
13%
Huntington's Disease
12%
Anaphase-promoting Complex
12%
Newly Diagnosed
12%
Local Control
12%
Dose Escalation
12%
Epigenetic Regulation
11%
Human Glioblastoma
11%
Hazard Ratio
10%
Atypical Meningioma
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Neurotoxicity
10%
Primary Brain Tumor
10%
Glioblastoma Cells
9%
IDH-mutant Glioma
9%
Glioblastoma multiforme
9%
Stem Cells
9%
Resection
9%
Grade II Meningioma
9%
Glioma Stem Cells
9%
Tumor Growth
8%
Tumor Volume
8%
Multivariate Analysis
8%
Machine Learning
8%
Magnetic Resonance Imaging Guided
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Concurrent Radiation
8%
Extent of Resection
8%
Phase 1/2 Study
8%
Stereotactic Laser Ablation
8%
Sex-determining Region Y-box 2 (SOX2)
8%
Medicine and Dentistry
Glioblastoma
70%
Neoplasm
68%
Surgery
42%
Brain Metastasis
26%
Magnetic Resonance Imaging
25%
Ganglioglioma
24%
Overall Survival
23%
Meningioma
23%
Radiation Therapy
23%
Progression Free Survival
20%
Stereotactic Radiosurgery
20%
Laser Surgery
19%
Recurrent Disease
15%
Intracranial Tumor
15%
Intraoperative MRI
15%
Biopsy Technique
13%
Transsphenoidal Surgery
12%
Tumor Progression
11%
Diseases
10%
Oligoastrocytoma
9%
Hazard Ratio
8%
Oligodendroglioma
8%
Circulating Tumor DNA
8%
Osteosarcoma
8%
Temozolomide
8%
Minimal Residual Disease
8%
Cushing Disease
8%
Immunotherapy
8%
Multivariate Analysis
8%
External Beam Radiotherapy
7%
Non Small Cell Lung Cancer
7%
Traumatic Brain Injury
7%
Melanoma
7%
Neuro-Oncology
7%
Surgeon
7%
Metastatic Carcinoma
6%
Endothelial Cell
6%
Disease
6%
Malignant Neoplasm
5%
Karnofsky Performance Status
5%
Isocitrate Dehydrogenase
5%
Vestibular Schwannoma
5%
Filum Terminale
5%
Adenoma
5%
Proportional Hazards Model
5%
Tumor Cell
5%
Systemic Therapy
5%
Bleeding
5%
Clinical Trial
5%
Radiosensitivity
5%